Conference call to be hosted on 30 March 2016 to present annual results 2015
Investors, financial analysts, and journalists interested in participating in the conference call can access via the following telephone numbers:
Date: 30 March 2016
Time: 3pm CEDT (9am EDT)
+49 89 2030 31217 (Germany)
+44 20 3427 1900 (UK)
+1 212 444 0895 (USA)
+49 89 2030 31217 (all other countries)
Conference ID: 9624550
A presentation document supporting the conference call will be available on 30 March 2016, on www.4sc.com in section "Investors & Media" / "Events & Presentations" / "Conference Calls & Webcasts". After the event, a replay can be accessed from there as well.
This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and 4SC AG has no obligation to update any such information or to correct any inaccuracies herein or omission herefrom which may become apparent.
Über die 4SC AG
4SC (www.4sc.com) is a biotechnology company dedicated to the research and development of small-molecule drugs focused on epigenetic mechanisms of action for the treatment of cancers with high unmet medical needs. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious than existing therapies, provide a better quality of life and offer increased life expectancy. The Company's pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies. Founded in 1997, 4SC had 67 employees (headcount) or 58 full-time equivalents (FTEs) at 31 December 2015. 4SC has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.